永泰生物-B(06978)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

06978 永泰生物-B

已收盘 12-08 16:08:08

2.960

-0.180

-5.73%

最高3.120	最低2.940	成交量369.84万
今开3.120	昨收3.140	日振幅5.73%
总市值18.29亿	流通市值18.29亿	总股本6.18亿
成交额1,124万	换手率0.60%	流通股本6.18亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"06978","market":"HK","secType":"STK","nameCN":"永泰生物-B","latestPrice":2.96,"timestamp":1765181288618,"preClose":3.14,"halted":0,"volume":3698400,"delay":0,"floatShares":618000000,"shares":618000000,"eps":-0.3998511970106053,"marketStatus":"已收盘","change":-0.18,"latestTime":"12-08 16:08:08","open":3.12,"high":3.12,"low":2.94,"amount":11238522,"amplitude":0.057325,"askPrice":2.97,"askSize":2000,"bidPrice":2.96,"bidSize":39000,"shortable":0,"etf":0,"ttmEps":-0.47812198433719005,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1765243800000},"marketStatusCode":5,"adr":0,"listingDate":1594310400000,"exchange":"SEHK","adjPreClose":3.14,"openAndCloseTimeList":[[1765157400000,1765166400000],[1765170000000,1765180800000]],"volumeRatio":1.471085,"lotSize":1000,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/06978","defaultTab":"news","newsList":[{"id":"2589433064","title":"全国首版商业保险创新药品目录发布，“深圳惠民保”率先落地","url":"https://stock-news.laohu8.com/highlight/detail?id=2589433064","media":"市场资讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589433064?lang=zh_cn&edition=full","pubTime":"2025-12-08 19:20","pubTimestamp":1765192800,"startTime":"0","endTime":"0","summary":"　　据悉，作为深圳本土普惠型商业健康保险，“深圳惠民保”已率先在2025年度保障中将这19种创新药全部纳入保障范围。所有参保“深圳惠民保”的深圳市民，在使用商保创新药目录的19种药品时，符合理赔待遇的均可报销，切实减轻购药自费负担，打通创新药可及性的“最后一公里”。“深圳惠民保”在国家医保药品目录外，为创新药费用保障缺口提供了重要补充，也是深圳多层次医疗保障体系的重要组成部分。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/insurance/bxyy/2025-12-08/doc-inhacaax3713437.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1574","06978","BK1161"],"gpt_icon":0},{"id":"2589391793","title":"远大医药(00512)：中药1类创新药GPN01360在中国开展的II期临床研究成功达到临床终点","url":"https://stock-news.laohu8.com/highlight/detail?id=2589391793","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589391793?lang=zh_cn&edition=full","pubTime":"2025-12-08 17:55","pubTimestamp":1765187758,"startTime":"0","endTime":"0","summary":"智通财经APP讯，远大医药 发布公告，近日，本集团用于治疗抑郁症的中药创新药GPN01360在中国开展的 II 期临床研究成功达到临床终点。此外，GPN01360安全性和耐受性较好，在整个试验期间未发现明显的毒副作用。前期近百人的人用经验研究表明，GPN01360在改善抑郁症状、缓解焦虑失眠及调理脾胃功能方面表现出良好疗效与安全性。因此，抑郁症的治疗仍存在较大未满足的临床需求，本集团的GPN01360有望为临床提供一种全新的治疗选择。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1378869.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["159992","06978","BK1574","01360","BK1137","00512","BK1191","BK1500","BK1161"],"gpt_icon":0},{"id":"2589833305","title":"一年两针！降脂创新药进医保，助力高效降脂疗法从“可用”走向“可及”","url":"https://stock-news.laohu8.com/highlight/detail?id=2589833305","media":"上观新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589833305?lang=zh_cn&edition=full","pubTime":"2025-12-08 16:56","pubTimestamp":1765184187,"startTime":"0","endTime":"0","summary":"国家医保目录再次迎来“全球新”。12月7日，《国家基本医疗保险、生育保险和工伤保险药品目录（2025年）》公布，这其中，全球首款PCSK9mRNA干扰类降胆固醇药物——乐可为（英克司兰钠注射液）成功纳入。这一备受关注的降脂创新药一年仅需注射两针，为相关患者提供全新治疗选择。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512083585350718.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["06978","159992","BK1574","BK1161"],"gpt_icon":0},{"id":"2589733333","title":"方盛制药(603998.SH)：中药创新药养血祛风止痛颗粒纳入国家医保目录","url":"https://stock-news.laohu8.com/highlight/detail?id=2589733333","media":"智通财经","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589733333?lang=zh_cn&edition=full","pubTime":"2025-12-08 16:51","pubTimestamp":1765183866,"startTime":"0","endTime":"0","summary":"智通财经APP讯，方盛制药(603998.SH)发布公告，公司全资子公司广东方盛健盟药业有限公司独家产品养血祛风止痛颗粒通过谈判首次纳入《国家基本医疗保险、生育保险和工伤保险药品目录》，公司及控股子公司其他主要产品本次无退出及增加至《2025版医保目录》的情况。养血祛风止痛颗粒为公司自主研发的中药创新药，本次经谈判首次被纳入《2025版医保目录》后，将有利于该产品未来的市场推广、医院准入及销售规模的提升，预计对公司未来的经营业绩、市场份额均能产生积极影响，但短期内不会对经营业绩产生重大影响。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1378792.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["159992","BK1161","BK1574","BK0239","BK0060","603998","06978"],"gpt_icon":0},{"id":"2589339203","title":"四环医药(00460)：创新药安久卫®成功续约纳入2025年国家基本医保药品目录","url":"https://stock-news.laohu8.com/highlight/detail?id=2589339203","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589339203?lang=zh_cn&edition=full","pubTime":"2025-12-08 16:42","pubTimestamp":1765183330,"startTime":"0","endTime":"0","summary":"作为首款且唯一国内自主研发的质子泵抑制剂，安久卫于2023年6月在中国获批上市，用于治疗十二指肠溃疡，并于2023年12月首次纳入国家基本医保药品目录。本次安久卫成功续约2025年国家基本医保药品目录，将利于稳定市场销售，继续惠及更多患者人群，提升该产品在相关适应症上的渗透率，为安久卫的长期增长注入动力。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1378783.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1515","00460","BK1600","BK1191","06978","BK1593","BK1161","BK1574","159992"],"gpt_icon":0},{"id":"2589386294","title":"摩根大通解密BD潮：巨头“抄底”中国创新药 下一个爆款在哪？","url":"https://stock-news.laohu8.com/highlight/detail?id=2589386294","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589386294?lang=zh_cn&edition=full","pubTime":"2025-12-08 12:42","pubTimestamp":1765168978,"startTime":"0","endTime":"0","summary":"【摩根大通解密BD潮：巨头“抄底”中国创新药 下一个爆款在哪？】刘伯伟分享了一个极具说服力的案例：一家大型MNC的CFO曾坦言，如果在中国采购同一管线的成本仅为美国的30%～40%，且可能获得更优的效果，他们必然选择中国。“成本与效果的极致平衡，正成为跨国药企将中国视为核心研发管线来源地的关键逻辑。”据摩根大通团队观察，当前除了持续火热的ADC、GLP-1等领域，跨国药企对中国在TCE（T细胞衔接器）、体内CAR-T、口服多肽及小核酸等前沿赛道的能力也表现出浓厚兴趣。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202512083585143680.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512083585143680.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["159992","LU1261432733.SGD","IE0034235295.USD","LU2237443382.USD","LU2552382132.HKD","LU0689472784.USD","LU1551013425.SGD","LU2237443978.SGD","LU2023250843.SGD","LU1084165304.USD","LU1551013342.USD","LU0267386448.USD","IE00BJTD4N35.SGD","LU0964807845.USD","LU0106261372.USD","LU2237443549.SGD","BK4207","LU0211327993.USD","BK4585","LU2552382215.SGD","BK4534","LU0310799852.SGD","LU0106831901.USD","LU2237443622.USD","LU0211328371.USD","LU0683600562.USD","JPM","LU0211326839.USD","LU0215105999.USD","06978","SG9999002232.USD","LU2456880835.USD","LU1366192091.USD","LU0238689110.USD","IE00BHPRN162.USD","LU0640476718.USD","LU0070302665.USD","LU1496350502.SGD","IE00BKDWB100.SGD","LU0820562030.AUD","LU0203345920.USD","LU0868494708.USD","LU0942090050.USD","LU1496350171.SGD","LU0345769631.USD","LU2552382058.USD","LU0265550359.USD","IE00BN8TJ469.HKD","LU2237443895.HKD","LU0882574139.USD"],"gpt_icon":0},{"id":"2589738572","title":"轩竹生物-B(02575)：创新药轩悦宁®首次纳入2025国家基本医保目录","url":"https://stock-news.laohu8.com/highlight/detail?id=2589738572","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589738572?lang=zh_cn&edition=full","pubTime":"2025-12-08 12:12","pubTimestamp":1765167154,"startTime":"0","endTime":"0","summary":"智通财经APP讯，轩竹生物-B(02575)发布公告，本公司自主研发的创新药吡洛西利片(商品名：轩悦宁®)首次纳入《国家基本医疗保险、生育保险和工伤保险药品目录( 2025年 )》(2025国家基本医保目录)。 2025国家基本医保目录将于2026年1月1日正式执行。本次医保谈判结果有助于本公司进一步提高轩悦宁®在患者中的可负担性和可及性，有利于进一步推动该药物的市场推广、提升销售规模，对本公司的长期经营发展具有积极影响。本公司将积极配合推进医保政策落地，持续推进医院准入工作、拓展核心市场及扩大市场的覆盖，以期不断提升患者的用药可及性。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1378677.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","BK1191","02575","06978","159992","BK1574"],"gpt_icon":0},{"id":"2589333580","title":"国金证券：从2025医保谈判看行业风向 成功率提升创新导向持续强化","url":"https://stock-news.laohu8.com/highlight/detail?id=2589333580","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589333580?lang=zh_cn&edition=full","pubTime":"2025-12-08 11:51","pubTimestamp":1765165873,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，国金证券发布研报称，2025年12月7日，国家医保局发布《2025新版基本医保药品目录》及首个《商业健康保险创新药品目录》，新版药品目录自2026年1月1日起正式执行。得益于创新药突出的临床价值，2025年新药谈判成功率较同期实现显著提升，此类药品预计将收获良好的谈判结果。CAR-T疗法因价格昂贵，曾多次无缘基本医保目录，此次全部成功纳入商保，具体协商价格暂未披露。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251208115342a43a7cc8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251208115342a43a7cc8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","LU2399975544.HKD","LU0561508036.HKD","LU0634319403.HKD","09926","IE00B5MMRT66.SGD","LU0417516738.SGD","IE00B543WZ88.USD","LU2476274308.USD","LU0348827113.USD","LU2488822045.USD","06990","LU0348735423.USD","LU0348767384.USD","LU0348825331.USD","BK1574","LU2476274720.SGD","LU0417516571.SGD","LU1720050803.USD","LU1961090484.USD","LU0348783233.USD","IE00BPRC5H50.USD","LU1794554557.SGD","02162","LU2778985437.USD","LU0540923850.HKD","LU0348784397.USD","LU0417516902.SGD","LU0348766576.USD","01276","06978"],"gpt_icon":0},{"id":"2589839923","title":"中信建投：创新药国谈成功率创新高 商保创新药目录提供增量","url":"https://stock-news.laohu8.com/highlight/detail?id=2589839923","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589839923?lang=zh_cn&edition=full","pubTime":"2025-12-08 11:21","pubTimestamp":1765164075,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，中信建投发布研报称，国家医保谈判成功率创历史新高，商保目录有望成为重要增量，政策鼓励创新药发展。看好相关创新药及制药企业。经调整后目录内药品总数达到3253种，其中西药1857种、中成药1396种。此外，19种药品纳入首版商保创新药目录。谈判成功率创7年新高，药物保障能力不断提升本次目录调整共有127个目录外药品参与谈判和竞价，其中114个药品谈判或竞价成功，总体成功率达88%。新版目录自2026年1月1日起正式执行。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1378652.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06978","BK0276","159992","BK1574","BK1161","601066"],"gpt_icon":0},{"id":"2589807750","title":"港股异动 | 绿叶制药(02186)涨近3% 米美欣®等五款新品获纳入国家医保药品目录或商保创新药目录","url":"https://stock-news.laohu8.com/highlight/detail?id=2589807750","media":"智通财经","labels":["productRelease","policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589807750?lang=zh_cn&edition=full","pubTime":"2025-12-08 09:48","pubTimestamp":1765158517,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，绿叶制药涨近3%，截至发稿，涨2.66%，报3.09港元，成交额837.51万港元。消息面上，12月7日，绿叶制药发布公告，集团共有五款新产品成功纳入由国家医疗保障局发布的《国家基本医疗保险、生育保险和工伤保险药品目录》或《商业健康保险创新药品目录》。该五款新产品包括：米美欣、瑞百莱首次纳入国家医保药品目录；赞必佳成功入选商保创新药目录；百拓维、瑞可妥顺利续约，继续被纳入国家医保药品目录。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1378607.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["159992","BK1191","BK1606","06978","BK1583","BK1574","BK1161","02186"],"gpt_icon":0},{"id":"2589807405","title":"药明巨诺-B盘中涨超9% 倍诺达®获纳入国家医保局商保创新药目录","url":"https://stock-news.laohu8.com/highlight/detail?id=2589807405","media":"新浪港股","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589807405?lang=zh_cn&edition=full","pubTime":"2025-12-08 09:48","pubTimestamp":1765158480,"startTime":"0","endTime":"0","summary":"　　药明巨诺-B盘中涨超9%，截至发稿，股价上涨4.55%，现报3.22港元，成交额373.07万港元。　　据药明巨诺-B官微消息，12月7日，公司宣布其首款中国自主研发、获批为1类新药的CAR-T产品倍诺达成功纳入首版国家医保局商业健康保险创新药品目录。在本次国家商保创新药目录建立之前，倍诺达凭借其显著的临床价值，已被纳入100多款普惠保和近100款百万医疗保险，在中国患者中得到大量临床实践和真实世界研究的充分验证。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2025-12-08/doc-infzzyrk3769500.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1583","BK1574","02126","BK1161","159992","06978"],"gpt_icon":0},{"id":"2589801092","title":"奥赛康(002755.SZ)：创新药利厄替尼片纳入国家医保目录","url":"https://stock-news.laohu8.com/highlight/detail?id=2589801092","media":"智通财经","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589801092?lang=zh_cn&edition=full","pubTime":"2025-12-08 08:05","pubTimestamp":1765152313,"startTime":"0","endTime":"0","summary":"智通财经APP讯，奥赛康 发布公告，根据国家医疗保障局、人力资源社会保障部于2025年12月7日发布的《关于印发<国家基本医疗保险、生育保险和工伤保险药品目录>以及<商业健康保险创新药品目录>的通知》，公司产品利厄替尼片纳入《国家基本医疗保险、生育保险和工伤保险药品目录》。利厄替尼片纳入国家医保目录，将进一步提高产品的可及性，有利于产品市场推广，对产品销售起到积极作用。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1378553.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0028","06978","BK1574","002755","BK1161","BK0239","159992"],"gpt_icon":0},{"id":"2589814801","title":"港股概念追踪 | 医保商保“双目录”出炉！多款创新药获纳入 行业望延续强劲发展势头(附概念股)","url":"https://stock-news.laohu8.com/highlight/detail?id=2589814801","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589814801?lang=zh_cn&edition=full","pubTime":"2025-12-08 07:17","pubTimestamp":1765149475,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，12月7日，国家医保局正式披露了最新一版的《国家基本医疗保险、生育保险和工伤保险药品目录》及2025年《商业健康保险创新药品目录》。今年是国家医保局自成立以来第八次对医保目录进行调整，也是首次在基本医保目录之外增设商保创新药目录。基本医保目录新增药品中，有50种是一类创新药，总体成功率88%，较2024年的76%明显提高。中泰证券认为，创新药行情有望持续。新版国家医保药品目录将于2026年1月1日起正式实施。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1378542.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","159992","06978","BK1161"],"gpt_icon":0},{"id":"2589809298","title":"翰森制药(03692)：创新药阿美乐®新增两项适应症成功纳入新版2025国家医保目录","url":"https://stock-news.laohu8.com/highlight/detail?id=2589809298","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589809298?lang=zh_cn&edition=full","pubTime":"2025-12-08 07:05","pubTimestamp":1765148745,"startTime":"0","endTime":"0","summary":"智通财经APP讯，翰森制药 发布公告，本集团创新药阿美乐新增两项适应症成功纳入新版《国家基本医疗保险、工伤保险和生育保险药品目录》，圣罗莱、恒沐所有适应症续约纳入2025国家医保目录，新版国家目录将于2026年1月1日正式实施。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1378537.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1589","06978","BK1583","159992","BK1191","BK1574","BK1161","03692"],"gpt_icon":0},{"id":"2589039807","title":"2025国谈落地：双管齐下 从“用得上”走向“用得起”","url":"https://stock-news.laohu8.com/highlight/detail?id=2589039807","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589039807?lang=zh_cn&edition=full","pubTime":"2025-12-08 00:09","pubTimestamp":1765123740,"startTime":"0","endTime":"0","summary":"2026年1月1日起，中国医保目录将迎来历史上规模最大的一次创新药扩容。新版医保目录将于2026年1月1日起正式实施。当创新药从“临床可用”迈向“医保可及”，一场深刻的产业变革正在悄然发生。诺华共有2个新产品及4个新适应症成功纳入2025年版国家医保药品目录。此次阿斯利康康可期纳入2025年国家医保目录，助力血液肿瘤患者“活得更长、活得更好”。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025120807455197953c25&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025120807455197953c25&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1587","02196","BK1574","BK1161","BK1585","06978","JNJ","02171"],"gpt_icon":0},{"id":"2589380386","title":"80%、50种，我国医保目录成为创新药快速落地“加速器”","url":"https://stock-news.laohu8.com/highlight/detail?id=2589380386","media":"动脉网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589380386?lang=zh_cn&edition=full","pubTime":"2025-12-07 23:22","pubTimestamp":1765120920,"startTime":"0","endTime":"0","summary":"我国已建立每年一调的医保目录动态调整机制，聚焦5年内新上市药品。2025年新纳入的114种药品中，多个实现当年获批上市即进目录。2018年以来，我国1类创新药获批数量明显上升，2024年达48种，医保目录成其快速落地“加速器”，推动市场扩容。药企研发投入有稳定回报预期，将激励更多药企加大创新研发，尤其针对肿瘤、罕见病等未满足需求领域。新药从获批到纳入医保报销的时间从5年缩短至1年左右，约80%的创新药能在上市两年内进目录。医保准入成市场拓展关键，通过“腾笼换鸟”优化资源配置，推动医药行业向高质量、创新型转型。目前，2025年国家医保药品目录内药品总数达3253种，1类创新药增至50种。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202512072346299794c403&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202512072346299794c403&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1969619763.USD","01877","09926","06160","06978","BK1161","09995","09688","BK1574","BK1583","LU2328871848.SGD"],"gpt_icon":0},{"id":"2589887431","title":"绿叶制药(02186)五款新产品成功纳入2025年国家医保药品目录或商保创新药目录","url":"https://stock-news.laohu8.com/highlight/detail?id=2589887431","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589887431?lang=zh_cn&edition=full","pubTime":"2025-12-07 18:43","pubTimestamp":1765104213,"startTime":"0","endTime":"0","summary":"智通财经APP讯，绿叶制药(02186)发布公告，集团共有五款新产品成功纳入由国家医疗保障局发布的《国家基本医疗保险、生育保险和工伤保险药品目录(2025年)》(国家医保药品目录)或《商业健康保险创新药品目录(2025年)》(商保创新药目录)。该五款新产品包括：米美欣®(羟考酮纳洛酮缓释片)、瑞百莱®(棕榈酸帕利哌酮注射液(Ⅱ))首次纳入国家医保药品目录;赞必佳®(注射用芦比替定)成功入选商保创新药目录;百拓维®(注射用戈舍瑞林微球)、瑞可妥®(注射用利培酮微球(Ⅱ))顺利续约，继续被纳入国家医保药品目录。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1378506.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06978","BK1583","159992","BK1191","BK1606","BK1574","BK1161","02186"],"gpt_icon":0},{"id":"2589879688","title":"华东医药最新公告：全资子公司产品及合作产品纳入国家医保及商保创新药目录","url":"https://stock-news.laohu8.com/highlight/detail?id=2589879688","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589879688?lang=zh_cn&edition=full","pubTime":"2025-12-07 16:20","pubTimestamp":1765095633,"startTime":"0","endTime":"0","summary":"华东医药(000963.SZ)公告称，公司全资子公司中美华东的乌司奴单抗注射液调整至常规目录管理，支付范围变动。合作产品塞纳帕利胶囊、戊二酸利那拉生酯胶囊被纳入新版药品目录，泽沃基奥仑赛注射液被纳入商保创新药目录。新版药品目录自2026年1月1日起执行，预计将有助于公司产品市场推广。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120700003965.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["06978","BK0132","BK0183","000963","BK0187","LU2328871848.SGD","BK1574","BK1161","LU1969619763.USD","BK0188","BK0196","BK0209","BK0175","159992"],"gpt_icon":0},{"id":"2589879103","title":"近半新增药品为一类新药！2025国谈结果公布：五款CAR-T均商保破冰 ，创新药支付迈入“价值时代”","url":"https://stock-news.laohu8.com/highlight/detail?id=2589879103","media":"智通财经网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589879103?lang=zh_cn&edition=full","pubTime":"2025-12-07 16:08","pubTimestamp":1765094886,"startTime":"0","endTime":"0","summary":"今日上午，在广州白云区举行的2025创新药高质量发展大会上，万众瞩目的年度医保准入大考——2025国谈结果正式揭晓。","market":"sh","thumbnail":"https://img.zhitongcaijing.com/image/20251207/20251207161234_79991.png?x-oss-process=image/format,jpg/quality,q_60","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20251207/20251207161234_79991.png?x-oss-process=image/format,jpg/quality,q_60"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1378479.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK1574","06978","BK4022","CAR","BK4230","BK1161","159992"],"gpt_icon":0},{"id":"2589879337","title":"艾力斯(688578.SH)：创新药伏美替尼、戈来雷塞纳入新版国家医保目录","url":"https://stock-news.laohu8.com/highlight/detail?id=2589879337","media":"智通财经","labels":["productRelease","policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589879337?lang=zh_cn&edition=full","pubTime":"2025-12-07 16:02","pubTimestamp":1765094576,"startTime":"0","endTime":"0","summary":"智通财经APP讯，艾力斯(688578.SH)发布公告，公司创新药品甲磺酸伏美替尼片(商品名“艾弗沙®️”，以下简称“伏美替尼”)和枸橼酸戈来雷塞片(商品名“艾瑞凯®️”，以下简称“戈来雷塞”)均被纳入《国家基本医疗保险、生育保险和工伤保险药品目录(2025年)》(以下简称“国家医保目录”)。其中，伏美替尼一线及二线治疗适应症经医保谈判后继续纳入国家医保目录;戈来雷塞二线治疗适应症通过医保谈判方式首次被纳入国家医保目录。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1378477.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688578","159992","BK0239","BK1574","06978","BK1161"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.eaal.net","stockEarnings":[{"period":"1week","weight":0.0363},{"period":"1month","weight":-0.0338},{"period":"3month","weight":-0.4142},{"period":"6month","weight":-0.0063},{"period":"1year","weight":0.4404},{"period":"ytd","weight":0.3652}],"compareEarnings":[{"period":"1week","weight":0.0087},{"period":"1month","weight":0.0058},{"period":"3month","weight":0.0262},{"period":"6month","weight":0.0964},{"period":"1year","weight":0.3336},{"period":"ytd","weight":0.3004}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"永泰生物制药有限公司是一家主要从事用于治疗癌症的细胞免疫产品的研发、制造及商业化的投资控股公司。该公司的非转基因细胞产品管线包括EAL和6B11-OCIK注射液。该公司的嵌合抗原受体T（CAR-T）细胞产品管线包括CAR-T-19注射液、迪诺仑赛注射液和aT19注射液。该公司的T细胞受体工程化T细胞疗法（TCR-T）细胞产品管线包括YT003、YT008及YT007。该公司主要在国内市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.6,"avgChangeRate":-0.065686},{"month":2,"riseRate":0.6,"avgChangeRate":0.206387},{"month":3,"riseRate":0.4,"avgChangeRate":-0.092735},{"month":4,"riseRate":0.2,"avgChangeRate":-0.078794},{"month":5,"riseRate":0.4,"avgChangeRate":-0.038349},{"month":6,"riseRate":0.8,"avgChangeRate":0.080731},{"month":7,"riseRate":0.2,"avgChangeRate":-0.000149},{"month":8,"riseRate":0.5,"avgChangeRate":0.012587},{"month":9,"riseRate":0.166667,"avgChangeRate":-0.035807},{"month":10,"riseRate":0.5,"avgChangeRate":-0.057833},{"month":11,"riseRate":0.5,"avgChangeRate":0.001253},{"month":12,"riseRate":0.833333,"avgChangeRate":0.07922}],"exchange":"SEHK","name":"永泰生物-B","nameEN":"IMMUNOTECH-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.10","shortVersion":"4.35.10","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"永泰生物-B(06978)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供永泰生物-B(06978)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"永泰生物-B,06978,永泰生物-B股票,永泰生物-B股票老虎,永泰生物-B股票老虎国际,永泰生物-B行情,永泰生物-B股票行情,永泰生物-B股价,永泰生物-B股市,永泰生物-B股票价格,永泰生物-B股票交易,永泰生物-B股票购买,永泰生物-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"永泰生物-B(06978)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供永泰生物-B(06978)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}